FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162666157> ?p ?o ?g. }

• W2162666157 endingPage "233" @default.
• W2162666157 startingPage "231" @default.
• W2162666157 abstract "When a woman is pregnant, especially for the first and second times, she is susceptible to more frequent and severe malaria infections than when she was not pregnant. These infections are associated with maternal anemia, premature deliveries, and low birth weight infants. In areas where malaria is endemic, strategies to control malaria during pregnancy include preventive measures, such as the use of insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment (IPTp), as well as case management as a curative measure. With regard to IPTp in the African Region, the World Health Organization (WHO) recommends 2 or 3 doses of sulfadoxine-pyrimethamine (SP) that are given during the second and third trimesters, at least 1 month apart [1]. This policy has been accepted by most African countries, and SP is delivered at routine antenatal visits. IPTp is being scaled up through reproductive health programs, particularly with funds from the Global Fund for the fight against Tuberculosis, AIDS, and Malaria. Results from other trials have shown that an additional dose of SP adds more benefit over the 2-dose regimen among human immunodeficiency virus (HIV)– infected women who are primiand secundi-gravidae [2]. Thus, the WHO recommends 2 or 3 doses of IPTp SP, with 3 doses being used where the prevalence of HIV infection among women is high. Some countries, such as Cameroon, have selected 3 doses of SP in their policy for all pregnant women, whereas some countries, such as Mali, chose 2 doses. In this issue of the journal, Maiga et al [3] report on a randomized clinical trial performed in Mali, which shows the superiority of 3 over 2 doses of IPTp SP for the prevention of placenta malaria and associated low birth weight infants. Mali, as the authors describe, has highly seasonal malaria transmission, moderate levels of ITN use, and low levels of SP resistance. Mali had adopted a 2-dose strategy in 2003. A survey of 1696 pregnant women during 2005–2007 showed that women who completed IPT SP early during the third trimester had reinfections later during the third trimester, meaning that the 2 doses provided insufficient protection. Therefore, the study reported in this issue was undertaken. Results of this randomized clinical trial clearly showed that adding a third dose of SP halved the risk of placenta malaria and low birth weight in all gravidae, compared with the standard 2-dose regimen. This study has therefore provided evidence that was needed in Mali, to move their policy from 2 to 3 doses. In the study design, the use of ITNs was not considered as a factor, most likely because Mali has moderate levels of ITN use. Studies from Kenya and the Gambia [2] have shown that IPTp SP provides less benefit to pregnant women who are using ITNs. Thus, increased use of ITNs may overcome the need for a third dose of SP, which would result in less use of SP by the population and, consequently, put less drug pressure on the parasite. Increased drug use and its consequence of drug pressure is an important factor that drives the development of drug-resistant parasites. Received 25 April 2011; accepted 29 April 2011. Correspondence: Rose Gana Fomban Leke, PhD, Department of Microbiology, Immunology and Hematology, Faculty of Medicine and Biomedical Sciences, Biotechnology Center, University of Yaounde 1, Yaounde, Cameroon (roseleke@ yahoo.com). Clinical Infectious Diseases 2011;53(3):231–233 The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. permissions@oup.com. 1058-4838/2011/533-0003$14.00 DOI: 10.1093/cid/cir383" @default.
• W2162666157 created "2016-06-24" @default.
• W2162666157 creator A5048668433 @default.
• W2162666157 creator A5057080428 @default.
• W2162666157 date "2011-08-01" @default.
• W2162666157 modified "2023-10-11" @default.
• W2162666157 title "The Use of Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine for Preventing Malaria in Pregnant Women" @default.
• W2162666157 cites W2102280420 @default.
• W2162666157 cites W2106552226 @default.
• W2162666157 cites W2141917084 @default.
• W2162666157 cites W2157428891 @default.
• W2162666157 doi "https://doi.org/10.1093/cid/cir383" @default.
• W2162666157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21765071" @default.
• W2162666157 hasPublicationYear "2011" @default.
• W2162666157 type Work @default.
• W2162666157 sameAs 2162666157 @default.
• W2162666157 citedByCount "7" @default.
• W2162666157 countsByYear W21626661572013 @default.
• W2162666157 countsByYear W21626661572014 @default.
• W2162666157 countsByYear W21626661572017 @default.
• W2162666157 countsByYear W21626661572018 @default.
• W2162666157 countsByYear W21626661572020 @default.
• W2162666157 crossrefType "journal-article" @default.
• W2162666157 hasAuthorship W2162666157A5048668433 @default.
• W2162666157 hasAuthorship W2162666157A5057080428 @default.
• W2162666157 hasBestOaLocation W21626661571 @default.
• W2162666157 hasConcept C131872663 @default.
• W2162666157 hasConcept C187212893 @default.
• W2162666157 hasConcept C203014093 @default.
• W2162666157 hasConcept C2777035104 @default.
• W2162666157 hasConcept C2777425658 @default.
• W2162666157 hasConcept C2778048844 @default.
• W2162666157 hasConcept C2778301690 @default.
• W2162666157 hasConcept C2779234561 @default.
• W2162666157 hasConcept C2780441369 @default.
• W2162666157 hasConcept C2908647359 @default.
• W2162666157 hasConcept C2910972410 @default.
• W2162666157 hasConcept C2986740045 @default.
• W2162666157 hasConcept C54355233 @default.
• W2162666157 hasConcept C71924100 @default.
• W2162666157 hasConcept C86803240 @default.
• W2162666157 hasConcept C99454951 @default.
• W2162666157 hasConceptScore W2162666157C131872663 @default.
• W2162666157 hasConceptScore W2162666157C187212893 @default.
• W2162666157 hasConceptScore W2162666157C203014093 @default.
• W2162666157 hasConceptScore W2162666157C2777035104 @default.
• W2162666157 hasConceptScore W2162666157C2777425658 @default.
• W2162666157 hasConceptScore W2162666157C2778048844 @default.
• W2162666157 hasConceptScore W2162666157C2778301690 @default.
• W2162666157 hasConceptScore W2162666157C2779234561 @default.
• W2162666157 hasConceptScore W2162666157C2780441369 @default.
• W2162666157 hasConceptScore W2162666157C2908647359 @default.
• W2162666157 hasConceptScore W2162666157C2910972410 @default.
• W2162666157 hasConceptScore W2162666157C2986740045 @default.
• W2162666157 hasConceptScore W2162666157C54355233 @default.
• W2162666157 hasConceptScore W2162666157C71924100 @default.
• W2162666157 hasConceptScore W2162666157C86803240 @default.
• W2162666157 hasConceptScore W2162666157C99454951 @default.
• W2162666157 hasIssue "3" @default.
• W2162666157 hasLocation W21626661571 @default.
• W2162666157 hasLocation W21626661572 @default.
• W2162666157 hasOpenAccess W2162666157 @default.
• W2162666157 hasPrimaryLocation W21626661571 @default.
• W2162666157 hasRelatedWork W1538644317 @default.
• W2162666157 hasRelatedWork W2025299049 @default.
• W2162666157 hasRelatedWork W2031068829 @default.
• W2162666157 hasRelatedWork W2122746108 @default.
• W2162666157 hasRelatedWork W2150002262 @default.
• W2162666157 hasRelatedWork W2162666157 @default.
• W2162666157 hasRelatedWork W2184548449 @default.
• W2162666157 hasRelatedWork W2510870154 @default.
• W2162666157 hasRelatedWork W2612790972 @default.
• W2162666157 hasRelatedWork W3194054890 @default.
• W2162666157 hasVolume "53" @default.
• W2162666157 isParatext "false" @default.
• W2162666157 isRetracted "false" @default.
• W2162666157 magId "2162666157" @default.
• W2162666157 workType "article" @default.